<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="67519"><DrugName>BO-110</DrugName><DrugSynonyms><Name><Value>BO-110</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>pIC-PEI, Bioncotech</Value></Name><Name><Value>dsRNA mimic (cancer), Bioncotech</Value></Name><Name><Value>polyinosine-polycytidylic acid-polyethyleneimine complex, Bioncotech</Value></Name></DrugSynonyms><CompanyOriginator id="1055622">Bioncotech Therapeutics SL</CompanyOriginator><CompaniesPrimary><Company id="1055622">Bioncotech Therapeutics SL</Company></CompaniesPrimary><CrossReferences><SourceEntity id="67519" type="Drug"><TargetEntity id="785186" type="siDrug">[pIC]PEI</TargetEntity></SourceEntity><SourceEntity id="1055622" type="Company"><TargetEntity id="5035561503" type="organizationId">Bioncotech Therapeutics SL</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="65713" type="Action"><TargetEntity id="5484" type="Mechanism">Interferon-induced Helicase C Domain-containing Protein 1 (MDA-5) Activators</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="68033" type="Action"><TargetEntity id="3626" type="Mechanism">Autophagy Inducers</TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity></SourceEntity><SourceEntity id="PTGT-11577" type="ciTarget"><TargetEntity id="1009331641353" type="siTarget">Interferon-induced helicase C domain-containing protein 1</TargetEntity><TargetEntity id="-37437764" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DR">Discovery</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="651">Cancer</Indication></IndicationsPrimary><ActionsPrimary><Action id="65713">IFN induced helicase C domain protein 1 stimulator</Action><Action id="68033">Autophagy protein stimulator</Action></ActionsPrimary><ActionsSecondary><Action id="1545">Anticancer</Action><Action id="1589">Apoptosis stimulator</Action><Action id="393">Immunostimulant</Action></ActionsSecondary><Technologies><Technology id="262">Oligonucleotide conjugated</Technology><Technology id="596">Injectable formulation</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology></Technologies><EphmraCodes><Ephmra><Code>L3</Code><Name>IMMUNOSTIMULATING AGENTS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-28T10:12:13.000Z</LastModificationDate><ChangeDateLast>2017-05-18T00:00:00.000Z</ChangeDateLast><AddedDate>2010-07-30T11:23:04.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1055622" linkType="Company"&gt;Bioncotech Therapeutics&lt;/ulink&gt; is investigating BO-110 (pIC-PEI), comprising the dsRNA mimic polyinosine-polycytidylic acid (pIC) complexed with polyethyleneimine (PEI) as a polycationic carrier for cytosolic delivery, which activates the helicase MDA-5 and leads to stimulation of autophagy, apoptosis and immune response,  for the potential injectable treatment of cancer including melanoma, glioblastoma, pancreatic and bladder cancer [&lt;ulink linkID="1120066" linkType="Reference"&gt;1120066&lt;/ulink&gt;], [&lt;ulink linkID="1218257" linkType="Reference"&gt;1218257&lt;/ulink&gt;], [&lt;ulink linkID="1282741" linkType="Reference"&gt;1282741&lt;/ulink&gt;], [&lt;ulink linkID="1283192" linkType="Reference"&gt;1283192&lt;/ulink&gt;], [&lt;ulink linkID="1293836" linkType="Reference"&gt;1293836&lt;/ulink&gt;], [&lt;ulink linkID="1499412" linkType="Reference"&gt;1499412&lt;/ulink&gt;]. In November 2013,  IND-enabling studies were underway [&lt;ulink linkID="1499412" linkType="Reference"&gt;1499412&lt;/ulink&gt;]. In November 2016, development was ongoing [&lt;ulink linkID="1872678" linkType="Reference"&gt;1872678&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In April 2012, the COMP of the EMA recommended the product be granted Orphan status for the treatment of pancreatic cancer [&lt;ulink linkID="1282741" linkType="Reference"&gt;1282741&lt;/ulink&gt;]; in June 2012, Orphan designation was granted [&lt;ulink linkID="1302032" linkType="Reference"&gt;1302032&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In November 2012, the company planned for phase I multi-tumor studies in the  fourth quarter of 2013 [&lt;ulink linkID="1342728" linkType="Reference"&gt;1342728&lt;/ulink&gt;]. in November 2012, the company planned for phase I studies and phase II  studies in 2013 and 2015 respectively [&lt;ulink linkID="1342728" linkType="Reference"&gt;1342728&lt;/ulink&gt;], [&lt;ulink linkID="1342748" linkType="Reference"&gt;1342748&lt;/ulink&gt;]; in November 2013, the company expected to initiate first-in-man clinical trials in mid-2014 [&lt;ulink linkID="1499412" linkType="Reference"&gt;1499412&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In November 2012, in vitro and in vivo data reported that the drug demonstrated therapeutic efficacy in treating melanoma, pancreatic cancer and glioblastoma. Data also reported that the drug prevented metastases in animal models and killed patient cancer stem cells  [&lt;ulink linkID="1342728" linkType="Reference"&gt;1342728&lt;/ulink&gt;].  In August 2011, the company planned to complete preclinical , phase I and phase II studies in 5 years [&lt;ulink linkID="1218257" linkType="Reference"&gt;1218257&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2010, preclinical studies had demonstrated that  BO-110 was effective in killing aggressive tumors without inducing secondary toxicities in various animal models [&lt;ulink linkID="1120066" linkType="Reference"&gt;1120066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2010, preclinical data were published. Studies with melanoma cells showed that pIC-PEI activated the helicase MDA-5, which leads to activation of the proapoptotic factor NOXA. The antitumoral activity of pIC-PEI was demonstrated in immunocompetent and immunosuppressed mice with xenografts of human melanoma cells grown as lung metastases, and in a genetically modified mouse that develops melanomas driven by activation of NRAS [&lt;ulink linkID="1283192" linkType="Reference"&gt;1283192&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1055622">Bioncotech Therapeutics SL</Company><Country id="ES">Spain</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-01-01T00:00:00.000Z</StatusDate><Source id="1283192" type="SERIAL"></Source></DevelopmentStatusCurrent></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1055622">Bioncotech Therapeutics SL</OwnerCompany><Country id="EU">EU</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="9">Withdrawn</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-12T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1055622">Bioncotech Therapeutics SL</OwnerCompany><Country id="EU">EU</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-06-06T00:00:00.000Z</MileStoneDate><Source id="1302032" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1055622">Bioncotech Therapeutics SL</OwnerCompany><Country id="EU">EU</Country><Indication id="249">Pancreas tumor</Indication><AwardedIndication>Treatment of pancreatic cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-04-12T00:00:00.000Z</MileStoneDate><Source id="1282741" type="PR"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-11577"><Name>IFN induced helicase C domain protein 1</Name><SwissprotNumbers><Swissprot>Q8R5F7</Swissprot><Swissprot>Q9BYX4</Swissprot></SwissprotNumbers></Target><Target id="PTGT-11933"><Name>Autophagy protein</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1055622">Bioncotech Therapeutics SL</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1060894">Reino de Espana</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="147526" title="Spanish Government to award Bioncotech Therapeutics funding for the development of BO-110 against cancer  "></Deal></Deals><PatentFamilies><PatentFamily id="1191709" number="WO-2011003883" title="Process for the identification of compounds for treating cancer"></PatentFamily><PatentFamily id="3668463" number="WO-2017085228" title="Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine"></PatentFamily><PatentFamily id="4275157" number="WO-2018210439" title="Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centro Nacional de Investigaciones Oncologicas" id="1017946"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bioncotech Therapeutics SL" id="1055622"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>